Last reviewed · How we verify
European Taxotere®
European Taxotere® is a Small molecule drug developed by Hospira, now a wholly owned subsidiary of Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | European Taxotere® |
|---|---|
| Sponsor | Hospira, now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (PHASE2)
- The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- European Taxotere® CI brief — competitive landscape report
- European Taxotere® updates RSS · CI watch RSS
- Hospira, now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about European Taxotere®
What is European Taxotere®?
European Taxotere® is a Small molecule drug developed by Hospira, now a wholly owned subsidiary of Pfizer.
Who makes European Taxotere®?
European Taxotere® is developed by Hospira, now a wholly owned subsidiary of Pfizer (see full Hospira, now a wholly owned subsidiary of Pfizer pipeline at /company/hospira-now-a-wholly-owned-subsidiary-of-pfizer).
What development phase is European Taxotere® in?
European Taxotere® is in Phase 1.